THE COMPLEMENT SYSTEM

1. THE COMPLEMENT SYSTEM

2. THE COMPLEMENT SYSTEM • The complementsystem is a set of plasmaproteinsthatactin a cascadetoattack and killextracellularpathogens. • Approximately 30 components: • activatingmolecules • regulator factors • complementreceptors • membraneproteinswichinhibitthelysis of hostcells • Most of thecomplementproteins and glycoproteinsareproducedintheliverin an inactiveform (zymogen). Activation is inducedbyproteoliticcleavage.

3. AMPLIFICATION OF THE COMPLEMENT CASCADE limited proteolysis inactive precursors enzyme activating surface Activating surface needed!

4. ACTIVATION OF THE COMPLEMENT SYSTEM COMPLEMENT ACTIVATION RECRUITMENT OF INFLAMMATORY CELLS OPSONIZATION OF PATHOGENS DIRECT KILLING OF PATHOGENS FACILITATING PHAGOCYTOSIS

5. ACTIVATION VIA THE CLASSICAL PATHWAY

6. THE C1 COMPLEX Collagen „legs” Gobular „heads” C1 is always present in serum but it can operate on an activating surface in normal case Low affinity binding to the Fc region of antibody  conformational change  activation Multiple interaction with immune complexes

9. Different isotypes of antibodies activate the complement system differently

10. The classical pathway: Fixation of complement, generation of C3b by the classical C3 convertase

11. ACTIVATION VIA THE MANNAN-BINDING LECTIN PATHWAY

12. Eukariotic cells Mannose GLYCOSYLATION OF PROTEINS IS DIFFERENT IN VARIOUS SPECIES Prokariotic cells Galactose Glucoseamine Neuraminic acid (sialic acid) Mannose

13. MANNAN-BINDING LEKTIN ACTIVATES THE COMPLEMENT SYSTEM MASP = MBL associated serin protease

14. ACTIVATION VIA THE ALTERNATIVE PATHWAY

15. C3b can derive from classical or the lectin pathway too Alternative pathway is instantly inactivated on eukariotic cell surfaces (in the presence of sialic acid molecules)

16. THE CENTRAL COMPONENT OF THE COMPLEMENT SYSTEM Complementfixation Strong covalent binding (3900000000000000 molecules/ml)

17. C5-CONVERTASE C3-convertase + C3b= C5-convertase (C4bC2bC3b) The classical and alternative C3-convertase is different in structure but common in function

18. MEMBRANE ATTACK COMPLEX (MAC) liveand dead bacteria MAC in the cell membrane

19. COMPLEMENT ACTIVATION SUMMARY

20. COMPLEMENT SYSTEM CLASSICAL PATHWAY MB-LECTIN PATHWAY ALTERNATIVE PATHWAY Antigen-antibody complex Mannose Pathogen surface MBL MASP-1/MASP-2 Serin protease C4, C2 C3 B, D C1q, C1r, C1s Serin protease C4, C2 C4a* C3a, C5a C3 CONVERTASE C3b Terminal C5b – C9 Inflammatory peptid mediators Phagocyte recruitment Opsonization Binding to phagocyte CR Immune complex removal MAC Pathogen/cell lysis

21. C3b C3b C3b C3b C3b inflammation phagocytosis The role of complement system in in vivo Alternative, lectin & classical pathway C3 MAC lysis C3a C4a C5a opsonization

22. Local inflammatory responses can be induced by the small complement fragments C3a, C4a, and especially C5a

23. bacterium complement receptor macrophage OPSONIZATION C3b

24. Complement receptors

25. ACTIVATION VIA THE CLASSICAL PATHWAY

27. REGULATION OF THE COMPLEMENT SYSTEM

29. Regulatory proteins on human cells protect them from complement-mediated attack

30. CD59 prevents assembly of terminal complement components into a membrane pore

31. Factor I DAF C1Inh C4bp CR1 MCP HRF C-pept.ase N CD59 S-protein DAF Fact-H CR1 MCP Factor I positive feedback Regulation of complement system a-2macrogl LECTIN PATHWAY Properdin membrane protein soluble molecule

32. MAJOR REGULATING FACTORS OF COMPLEMENT SYSTEM C1Inh: C1-inhibitor (serine-protease inhibitor) Factor I: inhibits both C3 convertases in the presence of co-factors (C4bp – classical pw., factor H – alternative pw., MCP – both) DAF(CD55): Decay Accelerating Factor MCP: Membrane Cofactor Protein MIRL(CD59): Membrane Inhibitor of Reactive Lysis Properdin: stabilize convertases of alternative pathway

33. Deficiencies of complement system – cascade molecules Not the lysis of cells is the most important function of the complement system

34. Deficiencies of regulatory molecules, receptors

35. One of the major function of C1 INHIBITOR C1q binds to IgM on bacterial surface C1q binds to at least two IgG molecules on bacterial surface Binding of C1q to Ig activates C1r, which cleaves and activates the serine protease C1s C1INH dissociates C1r and C1s from the active C1 complex

36. HEREDITARY ANGIONEUROTIC EDEMA (HANE)(HEREDITARY C1INH DEFECT) • 17-year old boy - severe abdominal pain (frequent sharp spasms, vomiting) • appendectomia  normal appendix • similar symptoms occured repeatedly earlier in his life with watery diarrhea • family history of prior illness • immunologist’s suspicion: hereditary angioneurotic edema • level of C1INH: 16% of the normal mean • daily doses of Winstrol (steroid) – marked diminution in the frequency and severity of symptoms • intravenous purified C1INH became avaible by the time Main symptoms: • swellings of skin, guts, respiratory tracts • serious acute abdominal pain, vomiting • larynx swelling – suffocation, may cause death Treatment: • iv C1INH, FFP, steroid • kallikrein and bradykinin receptor antagonists Child with symptoms of HANE

37. Pathogenesis of hereditary angioneurotic edema Inhibition by C1INH in many steps activation of XII factor • bradykinin and C2-kinin: enhance the permeability of postcapillar venules by contraction of endothel • holes in the venule walls • edema formation • C1 is always active without activating surface because plasmine is always active activation of kallikrein activation of proactivator cleveage of kininogen to generate bradykinin, vasoactive peptide cleveage of C2a to generate C2-kinin, vasoactive peptide cleveage of plasminogen to generate plasmin cleveage of C2 to generate C2a activation of C1

38. Q&A HANE 1. Activation of complement system results in the release of histamine and chemokines, which normally produce pain, heat and itching. Why is the edema fluid in HANE free of cellular components, and why does the swelling not itch? Histamine release on complement activation and recruiting of leukocytes is caused by C3a and C5a, both generated by the C3/C5 convertases. In HANE C1 constantly activate C2 and C4 in the plasma but C4b is rapidly inactivated because it does not bind to activating surface; for that reason, and because the concentrations of C2 and C4 are relatively low, no C3/C5 convertase is formed. Edema is caused by C2-kinin and bradykinin. 2.Which complement component levels will be decreased? Why? C2 and C4, because of the continous cleavage by activated C1.

39. Q&A HANE 3. Would you expect the alternative pathway components to be low, normal or elevated? C1 plays no part in the alternative pathway. This pathway is not affected. 4. What about the levels of the terminal components? The unregulated activation of the early components does not lead to the formation of the C3/C5 convertase, so the terminal components are not abnormally activated. 5. Despite the complement deficiency in patients with HANE, they are not unduly susceptible to infection. Why not? The alternative pathway of complement activation is intact and these are compensated for by the potent amplification step from the alternative pathway. 6. How might you decide the background of the laryngeal edema (HANO or anaphylactic reaction)? If the laryngeal edema is anaphylactic, it will respond to epinephrine. If it is due to HANO, it will not, C1INH needed.

40. PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) • Acquired clonal mutation of PIG-A gene in myeloid progenitors – no GPI-enchored proteins in the cell membrane of affected cells (rbc, plt, wbc) • CD59 and CD55 complement regulatory proteins are GPI-enchored proteins • No CD59 and/or CD55  PNH patients are highly susceptible to complement-mediated lysis • The lysis of red blood cells leads to high levels of hemoglobins in the blood that appears in the urine (hemoglobinuria) • Elevated levels of TF derived from complement-damaged leukocytes cause thromboses

41. Change in the colour of urine samples taken from PNH patient during the day

42. Haemolytic anaemia and associated symptoms Haemoglobin and its products in the urine Thrombosis: brain veins, mesentheric veins, hepatic veins (Budd-Chiari-syndrome) Chance of transformation to acut myelogenous leukemia (AML), aplastic anaemia, myelodisplastic syndrome (MDS) Specific th.: eculizumab (Soliris) - anti-C5 monoclonal antibody Curative th.: bone marrow transplantation Alternative th.: steroids (general immunosuppression) Anticoagulants: sc. heparin  p.o. kumarin Iron replacement Transfusion (filtered-irradiated blood) Paroxysmal nocturnal hemoglobinuria (PNH) symptoms and therapy

43. Abbreviations C1Inh: inhibitor of C1 and MBL (serin protease inhibitor – multiple effects) α2-macroglobulin: inhibitor of MBL C4bp: C4 binding protein - inhibitor of the classical C3 convertase Factor H: inhibitor of the alternative C3 convertase Factor I: cleavesC4b and C3b Properdin: stabilizes the convertases of the alternative pathway DAF (CD55): Decay Accelerating Factor (of C3 convertases) MCP (CD46): Membrane Cofactor Protein, cleavage of C3 convertases with factor I CR1: complement receptor 1, inhibitor of C3 convertases CD59 (MIRL): Membrane Inhibitor of Reactive Lysis – inhibits binding of C9 to C8 HRF: Homologous Restriction Factor (inhibits binding of C8 and C9)